IS-004

IS-004 is a chimeric antigen receptor T-cell (CAR-T) therapy currently in preclinical development by ImmunoScape as part of a partner program. While ImmunoScape primarily focuses on T-cell receptor (TCR-T) therapies identified through its Deep Immunomics platform, IS-004 represents an expansion into the CAR-T modality. The specific target antigen and the primary disease indications for this program are currently undisclosed. The therapy is designed to engineer T cells to express a synthetic receptor that targets specific surface proteins on cancer cells, facilitating their destruction.

Other names

IS-004-ImmunoScape-CAR-T cell therapyIS004-ImmunoScape-CAR-T cell therapyIS 004-ImmunoScape-CAR-T cell therapy